Innovative Industrial Boosts Funding for Massachusetts Asset
Innovative Industrial Properties IIPR recently announced entering into an amendment of lease and development agreement with a subsidiary of PharmaCann LLC (PharmaCann), offering an additional funding of $8 million. This financing will support expansion of PharmaCann’s regulated cannabis cultivation and processing facilities at a property in Holliston, MA.
The move also led to the adjustment of the base rent under the lease to incorporate the impact of additional available funding as well as extension of the lease agreement term. Considering full payment of the supplementary funding, cannabis-focused real estate company Innovative Industrial Properties’ total investment in the property, which it originally acquired and entered into a long-term lease with PharmaCann in 2018, will reach $26.5 million.
The partnership with PharmaCann, a multi-state cannabis operator, has taken place earlier as well, and the move will help Innovative Industrial Properties efficiently capitalize on the healthy market fundamentals. In fact, Innovative Industrial Properties has already partnered with PharmaCann for facilities in New York, Ohio and Pennsylvania, with the Pennsylvania transaction closing last month only.
Notably, the legalization of marijuana’s medical use in several states as well as permission of adult consumption in some states has opened up opportunities for the cannabis industry. Therefore, with more states in the United States giving cannabis the green light, Innovative Industrial Properties has incentive to partner with experienced medical-use cannabis operators and serve as a source of capital by acquiring and leasing back their real estate assets.
Particularly, Massachusetts is providing significant growth opportunities to the cannabis industry. In fact, in the first six full months since Massachusetts launched its regulated adult-use cannabis program, i.e. from December 2018 through May 2019, aggregate adult-use cannabis sales approximated $140 million, according to Marijuana Business Daily. This figure included $34 million in May sales only. Also, the regulations were approved by Massachusetts regulators recently, which govern cannabis cafes and delivery, offering several channels for business expansion.
Innovative Industrial Properties currently carries a Zacks Rank #2 (Buy). In the year-to-date period, shares of the company have outperformed the industry. While the stock has surged 101.4%, the industry has gained 24.9% during this period. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Key Picks
Investors can also consider some similar-ranked stocks from the real estate space like Alexandria Real Estate Equities, Inc. ARE, Equity Residential EQR and Mid-America Apartment Communities, Inc. MAA.
Alexandria Real Estate’s Zacks Consensus Estimate for 2019 funds from operations (FFO) per share has moved marginally north to $6.98 in the past three months.
Equity Residential’s FFO per share estimate for the current year moved up 0.3% to $3.45 over the past month.
Mid-America’s Zacks Consensus Estimate for the ongoing year’s FFO per share climbed marginally to $6.30 in a month’s time.
Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Click to get this free report
Mid-America Apartment Communities, Inc. (MAA): Free Stock Analysis Report
Equity Residential (EQR): Free Stock Analysis Report
Alexandria Real Estate Equities, Inc. (ARE): Free Stock Analysis Report
Innovative Industrial Properties, Inc. (IIPR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research